Cizzle Biotechnology Holdings PLC
CIZ
Company Profile
Business description
Cizzle Biotechnology Holdings PLC is in the early stages of developing a blood test for the early detection of a majority of the different forms of lung cancer. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of C1Z1 known as CIZ1B. C1Z1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted C1Z1B variant is correlated with early stage lung cancer.
Contact
C/o SGH Secretaries Limited
60 Gracechurch Street
6th Floor
LondonEC3V 0HR
GBRE: cizzle@investor-focus.co.uk
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
2
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,464.20 | 42.50 | 0.50% |
| CAC 40 | 7,694.44 | 67.60 | 0.89% |
| DAX 40 | 23,352.69 | 236.73 | 1.02% |
| Dow JONES (US) | 41,368.45 | 254.48 | 0.62% |
| FTSE 100 | 8,531.61 | 27.72 | -0.32% |
| HKSE | 22,778.63 | 2.71 | 0.01% |
| NASDAQ | 17,928.14 | 189.98 | 1.07% |
| Nikkei 225 | 37,476.25 | 547.62 | 1.48% |
| NZX 50 Index | 12,605.07 | 138.04 | 1.11% |
| S&P 500 | 5,663.94 | 32.66 | 0.58% |
| S&P/ASX 200 | 8,234.10 | 42.40 | 0.52% |
| SSE Composite Index | 3,344.19 | 7.81 | -0.23% |